Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

Dr. de Min brings over 25 years' experience in drug development in both big pharma and biotechShe will drive the advancement of Topas' development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for …